



Quality transfusion diagnostics products.

41 University Drive, Ste 400 | Newtown, Pennsylvania 18940 | T 888-284-1901 | F 888-694-5208 | W quotientbd.com

CONTACT:

Michael Hannan
Quotient Biodiagnostics
215-497-8821
michael.hannan@quotientbd.com

FOR IMMEDIATE RELEASE

**QUOTIENT BIODIAGNOSTICS SIGNS AGREEMENT TO SUPPLY BLOOD BANK REAGENTS TO
BLOOD GROUP ALLIANCE (BGA)**

BGA IS A BUYING COOPERATIVE REPRESENTING 69 INDEPENDENT BLOOD CENTER MEMBERS

NEWTOWN, PA (December 13, 2010) Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today announced that it has entered into a supply agreement with Blood Group Alliance (BGA). BGA will promote Quotient's product line to its blood center member organizations, which account for over 50% percent of the nation's transfusion requirements. The agreement includes Quotient's first 24 products in its proprietary line of manual transfusion diagnostics as well as future products when approved by the U.S. Food & Drug Administration (FDA).

"We are excited not just to count the BGA membership among our growing list of customers, but we are also honored by the confidence the membership as shown in Quotient to be one of its few approved suppliers of blood bank reagents" said Michael Hannan, V.P., Marketing & Commercial Development, Quotient Biodiagnostics. "We look forward to a long and productive relationship, as we continue to build our reputation in the US as an innovative company focused on the needs of our customers."

Formed in 2009 to bring its products to the US market, Quotient Biodiagnostics sells its proprietary line of antisera products under the trade names ALBAclone[®], ALBAcyte[®], ALBAcheck[®], ALBAhance[™], and ALBAlect[™]. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions at a reasonable cost.

Quotient Biodiagnostics' current portfolio now includes products used in ABO blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-A₁; Rh typing reagents including four Anti-D products, Rh Control, Anti-E, and Anti-c; and rare anti-sera including Anti-k, Anti-M, Anti-N, Anti-Le^a, Anti-Le^b, and Anti-Lu^b – all monoclonal antibodies. Quotient also has three enhancement media products on the market including Bovine Serum Albumin 22%, PEG and LISS Additive.

In addition, Quotient recently launched the first of its red blood cell products, IgG sensitized cells, a surprisingly large component of a blood bank's budget.

As well, Quotient has three specialty kits in its current portfolio including the ALBAcheck[®] Competency Training Kit, which includes a collection of 20 blinded antibody samples that can be used to train or evaluate staff competency Identifying; the ALBAclone[®] Advanced Partial RhD Typing Kit, which identifies weak and partial RhD types with results comparable to molecular analysis at a fraction of the cost; Quant-Rho[®] FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. Finally, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete its full portfolio of manual reagents of nearly 75 products.

“We are delighted to establish the agreement with Quotient to give all BGA members access to this agreement. As a new entrant to this market, Quotient represents some fresh and innovative approaches to meeting blood center needs in the areas of transfusion diagnostics products” said Charlie Mosher, Chairman, Blood Group Alliance, Inc.

Since announcing its expansion into the U.S. transfusion market in 2009, Quotient Biodiagnostics has made significant progress in building its customer base and product use, supported by its more than 30 years of experience in Europe and other markets, quality manufacturing and commitment to service excellence.

Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visit www.quotientbd.com, or call the customer service line 888-284-1901, or e-mail customer.service@quotientbd.com.

About Blood Group Alliance:

Blood Group Alliance is a cooperative with sixty-nine independent blood center organizations as members. BGA was initiated as a collaborative effort of Blood Centers of America and Group Services for America's Blood Centers to provide certain services to member blood centers. These services include the management of recovered plasma used for producing therapeutic proteins, a common hospital GPO relationship, cell therapy support services, vendor qualification and supply chain projects.

About Quotient Biodiagnostics:

Quotient Biodiagnostics Group, through its wholly owned subsidiary, Alba Bioscience, brings over 30 years of experience in the transfusion medicine market. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient's goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation to market and sell the Group's blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.